Significantly, AML1 mutations account for 33.3% of CML-BC patients, while no such mutation was detected in CML-CP samples [16], suggesting that AML1 mutants contribute to the transition from CML-CP to CML-BC. Here, RUNX1 is linked to breast cancer.